Mill Creek Life Sciences Announces Certification To ISO 9001:2015
ROCHESTER, Minn., Nov. 8, 2018 /PRNewswire/ -- Mill Creek Life Sciences, LLC (Mill Creek), a Rochester, MN based start-up that provides tools to support the development and application of cellular and biological therapeutics, is pleased to announce they have been certified under ISO 9001:2015 by DNV GL, effective September 10, 2018.
International Organization for Standardization (ISO) is devoted to promoting the use of common standards as a means of aligning quality and business strategy to facilitate world trade and safeguard customers. ISO 9001:2015 provides standardized criteria for the development, use, and maintenance of a Quality Management System committed to delivering quality products and services through quality awareness, continuous improvement, and dedication to customer satisfaction.
"We are very pleased to have earned ISO 9001:2015 certification and feel it aligns well with Mill Creek's continual commitment to quality. A lot of time and hard work went into this achievement and I'd like to thank the Mill Creek team for their leadership in the effort," said Bill Mirsch, Chief Executive Officer of Mill Creek Life Sciences. "ISO 9001:2015 certification is an important step in progressing as a company and best serving our customers in the cellular therapy arena."
About Mill Creek Life Sciences
Mill Creek Life Sciences (www.millcreekls.com) is the first company to commercialize human platelet lysate for cellular therapy. A spin-off out of the Human Cell Therapy Laboratory at the Mayo Clinic in Rochester, MN, Mill Creek has been involved in clinical cellular therapies from the beginning. Mill Creek is dedicated to providing the highest quality products for the research and clinical community.
To stay in touch with Mill Creek Life Sciences, follow us on Facebook, Twitter, and LinkedIn.
SOURCE Mill Creek Life Sciences, LLC
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article